Recorded Presentation from the NCCN Pharmacy Updates: Current Therapy Options for Graft-Versus-Host Disease |
1.00 |
04/07/2020 - 12:00am to 04/01/2021 - 12:00am |
NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020 |
1.00 |
04/10/2020 - 12:00am to 04/10/2021 - 12:00am |
Talking to Patients about Cancer Treatment, Risk Factors, and Treatment Cessation during the COVID-19 Pandemic |
1.00 |
04/20/2020 - 12:00am to 04/20/2021 - 12:00am |
BCOP Test - New Targets and Treatment Options for Acute Myeloid Leukemia |
|
04/28/2020 - 2:00pm to 04/28/2021 - 12:00am |
Recorded Presentation from the NCCN Pharmacy Updates: New Targets and Treatment Options for Acute Myeloid Leukemia |
1.00 |
04/30/2020 - 12:00am to 04/28/2021 - 12:00am |
Practical Use of Next Generation Sequencing in Metastatic Disease |
0.50 |
05/08/2020 - 12:00am to 03/01/2021 - 12:00am |
Treatment Considerations in Older Adult Oncology |
0.75 |
05/08/2020 - 12:00am to 03/01/2021 - 12:00am |
Immune Checkpoint Inhibitor Toxicities |
0.75 |
05/08/2020 - 12:00am to 03/01/2021 - 12:00am |
The Role of Biosimilars in Cancer Treatment |
0.75 |
05/08/2020 - 12:00am to 03/01/2021 - 12:00am |
The Role of Integrative Medicine in Cancer |
0.75 |
05/08/2020 - 12:00am to 03/01/2021 - 12:00am |
Molecular Testing Updates and Impact for Clinical Practice |
0.75 |
05/08/2020 - 12:00am to 03/01/2021 - 12:00am |
NCCN Guidelines® Insights - Primary Cutaneous Lymphomas, Version 2.2020 |
1.00 |
05/10/2020 - 12:00am to 05/10/2021 - 12:00am |
New Approaches to Multiple Myeloma Therapy |
1.00 |
05/12/2020 - 12:00am to 05/12/2021 - 12:00am |
Recognition and Management of Graft Versus Host Disease |
1.00 |
05/12/2020 - 12:00am to 03/01/2021 - 12:00am |
Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers |
1.25 |
05/15/2020 - 12:00am to 03/01/2021 - 12:00am |